SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by anticipation for upcoming clinical data presentations and a potential BLA submission later this year. The community is actively discussing the stock's high short interest and limited effective float, fueling speculation about a possible short squeeze and long-term valuation potential relative to sector peers.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Dow Inc. is trending as investors weigh significant operational challenges against potential strategic upside, including recent job cut announcements and efforts to optimize EBITDA. The community remains divided, with some traders debating whether the stock is a deep-value opportunity for long-term recovery and dividend income, while others express frustration over persistent weak demand and ongoing supply chain headwinds.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF is trending as investors capitalize on surging worldwide military spending and a shift toward tech-driven, autonomous warfare. The community is actively discussing its potential for long-term growth driven by geopolitical tensions, with many highlighting its strategic exposure to both domestic defense contractors and international aerospace leaders.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is facing extreme selling pressure and intense community scrutiny as investors grapple with multiple compression, executive departures, and a lack of positive guidance. While some see a generational buying opportunity near multi-year lows, others remain deeply frustrated by the stock's persistent underperformance and the CEO's lack of communication regarding rumored AI-driven catalysts.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently trending as investors weigh its role as a high-beta proxy for Bitcoin against broader concerns over the Clarity Act, which remains a key focus for market participants anticipating potential regulatory shifts. The community is actively discussing Coinbase's technical setup and its correlation with BTC, with many traders debating whether the stock is setting up for a rebound or facing further downside risk.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing intense downward pressure despite fresh capital injections from the Saudi PIF and Uber, as investors express skepticism over persistent dilution and the appointment of a new CEO with an industrial, non-automotive background. The community is sharply divided, with bulls pointing to the company's advanced EV technology and long-term potential in the robotaxi market, while bears remain focused on high cash burn, recurring share offerings, and the risk of further reverse splits.

VanEck ETF Trust - VanEck Junior Gold Miners ETF

VanEck Junior Gold Miners ETF

Junior gold miners are capturing significant attention as the ETF demonstrates a robust nested impulse rally, signaling strong bullish momentum that has the community actively debating the durability of the sector's breakout. Investors are closely monitoring the interplay between record gold prices and the sector's valuation, with many bullish traders viewing any short-term volatility as a strategic accumulation opportunity.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is generating buzz as investors speculate on a potential supply shock due to its limited 10 million token cap, while the community closely monitors potential institutional interest and upcoming decentralized finance (DeFi) developments. Despite varied sentiment regarding historical performance, the discussion is heavily fueled by anticipation of broader market momentum and the potential for a reversal as traders track key support and resistance levels.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors react to a significant volume of convertible note offerings, causing short-term price volatility while fueling speculation about strategic acquisitions or pipeline expansions. Meanwhile, the community remains divided between long-term bulls highlighting strong institutional backing and a robust clinical pipeline, and frustrated retail holders concerned by management's dilution strategy and the stock's struggle to maintain upward momentum.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently in the spotlight as investors brace for the upcoming BlueBird 7 launch, with the community actively debating whether the stock is primed for a major breakout or if the event remains priced in. Investors are closely monitoring manufacturing progress and batch shipment updates as key catalysts, while discussions remain polarized between those confident in long-term deployment goals and others wary of execution timelines and institutional selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?

Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 16, 2026 Insiders may stand to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS...

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA...

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Barinthus Biotherapeutics (BRNS) announced on Tuesday that it will merge with Clywedog Therapeutics in an all-stock transaction. Following the announcement, the company's shares slid 7% in the pre-market session.Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share (ADS) or ordinary share they own. Meanwhile, each stockholder of Clywedog will receive 4.358932 shares of common stock in the new combined company for every common or preferred share they own. The combined company will advance a fresh portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-biotherapeutics-combine-clywedog-therapeutics-target">said</a>. Four clinical data milestones are expected within 18 months of transaction closing, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BRNS">BRNS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.The combined company will be renamed “Clywedog Therapeutics, Inc.” and is expected to trade on the Nasdaq under the new ticker symbol “CLYD.” Barinthus Bio ADSs will no longer trade on the Nasdaq following the closing of the transaction in the first half of 2026.The combined company will initially focus on advancing its pipeline in Type 1 diabetes, Type 2 diabetes, and celiac disease, Barinthus said. It is expected to have a cash runway into 2027 with additional investments from Clywedog’s existing investors, OrbiMed and Torrey Pines Investment LLC.Upon closing, shareholders of Barinthus Bio are expected to own approximately 34%, and the stockholders of Clywedog are expected to own approximately 66% of the combined company on a fully diluted basis.BRNS shares are up by 22% this year and 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.

Equity

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.


Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

Current Price	$0.59
Prev Close	$0.591
Open	$0.59
Dividend Yield	0.00%
50-Day Moving Average	$0.6049
Beta	0.69
Avg. Volume	33,574.65
PE Ratio	-0.36

52-Week High	$2.92
52-Week Low	$0.512
Market Capitalization	$24.1M
EPS (Annual)	-$1.64
Price to Book	0.33
Revenue Per Employee	$0.00

BRNS
Barinthus Biotherapeutics PLC - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BRNS News

BRNSBarinthus Biotherapeutics PLC - ADR